Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM Peptide Libraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | The promise of billion-dollar KRAS drugsGo to article: In this issueGo to article: ContentsGo to article:  Wek-tec Company InsightGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: AgilentGo to article: CommentGo to article: The potential of virtual reality-based therapy for serious mental disordersGo to article: Brazil: an untapped market for big pharma manufacturingGo to article: More big wins for the AstraZeneca-Daiichi Sankyo collaborationGo to article: Dry powder inhalers carry potential to decrease greenhouse emissionsGo to article: Black participants severely underrepresented in global oncology studiesGo to article: Polio outbreak in New York state due to low vaccination coverageGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: SkyepharmaGo to article: In DepthGo to article: Exploring the promise of billion-dollar KRAS drugsGo to article: Nanorobots: small solutions to big delivery problemsGo to article: Foreign investments amplify the nucleic acid therapeutics fieldGo to article: Going beyond the mirage of complete skin clearance in psoriasisGo to article: As Russia’s clinical trials sector falls, Ukraine rebuildsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing—SeptemberGo to article: Dr. Paul LohmannGo to article: BaxterGo to article: In DataGo to article: Top pharma companies best positioned to weather industry disruptionGo to article: Which pharma companies lead the way in artificial intelligence?Go to article: North America sees a hiring jump in big data roles in pharmaGo to article: Cloud computing mentions decrease in pharma filingsGo to article: EventsGo to article: Next issue